Pharmacokinetic and pharmacodynamic effects of ravulizumab and eculizumab on complement component 5 in adults with paroxysmal nocturnal haemoglobinuria: results of two phase 3 randomised, multicentre studies

Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab

(2019) Kioa Lente Wijnsma et al.   CLINICAL PHARMACOKINETICS

Design and preclinical characterization of ALXN1210: A novel anti-C5 antibody with extended duration of action

(2018) Douglas Sheridan et al.   PLoS One

Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study

(2018) Austin G. Kulasekararaj et al.   BLOOD

Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study

(2018) Jong Wook Lee et al.   BLOOD

Fixed Dosing of Monoclonal Antibodies in Oncology

(2017) Jeroen J.M.A. Hendrikx et al.   ONCOLOGIST

Evaluation of dosing strategy for pembrolizumab for oncology indications

(2017) Tomoko Freshwater et al.   Journal for ImmunoTherapy of Cancer

Eculizumab Dosing Intervals Longer than 17 Days May Be Associated with Greater Risk of Breakthrough Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria

(2016) Hirokazu Nakayama et al.   BIOLOGICAL & PHARMACEUTICAL BULLETIN

Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation

(2016) Markus J. Harder et al.   BLOOD

Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab

(2014) R. Peffault de Latour et al.   BLOOD

Efficacy and safety of eculizumab in children and adolescents with paroxysmal nocturnal hemoglobinuria

(2014) Ulrike M. Reiss et al.   PEDIATRIC BLOOD & CANCER

Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria

(2013) Peter Hillmen et al.   BRITISH JOURNAL OF HAEMATOLOGY

A Guide to Rational Dosing of Monoclonal Antibodies

(2012) Shuang Bai et al.   CLINICAL PHARMACOKINETICS

Fixed Dosing Versus Body Size-Based Dosing of Monoclonal Antibodies in Adult Clinical Trials

(2009) Diane D. Wang et al.   JOURNAL OF CLINICAL PHARMACOLOGY